Treatment of intestinal and hepatic mucormycosis in an immunocompromized child

Pediatr Blood Cancer. 2009 Jul;52(7):872-4. doi: 10.1002/pbc.21918.

Abstract

During ALL chemotherapy, a 4-year-old patient presented with febrile neutropenia and abdominal pain. Ultrasound examinations were repeatedly normal. Computerized tomography on day 7 demonstrated appendicitis and multiple hepatic foci identified as mucormycosis (Absidia corymbifera). Successful outcome was achieved by aggressive re-surgery, long-term antifungal therapy with serum level-monitored posaconazole, and recovery of neutrophil counts. Considering the interference of posaconazole with CYP3A4, vincristine was administered during 72 hr posaconazole windows. Pediatric intestinal mucormycosis, still associated with a >70% case-fatality rate, calls for early imaging and surgery to establish the diagnosis, reduce the fungal mass, and provide a rationale for using posaconazole.

Publication types

  • Case Reports

MeSH terms

  • Antifungal Agents / therapeutic use
  • Antineoplastic Agents, Phytogenic / therapeutic use
  • Child, Preschool
  • Drug Therapy, Combination
  • Humans
  • Immunocompromised Host*
  • Intestinal Diseases / diagnostic imaging
  • Intestinal Diseases / drug therapy*
  • Intestinal Diseases / microbiology
  • Liver Diseases / diagnostic imaging
  • Liver Diseases / drug therapy*
  • Liver Diseases / microbiology
  • Magnetic Resonance Imaging
  • Male
  • Mucormycosis / diagnostic imaging
  • Mucormycosis / drug therapy*
  • Mucormycosis / microbiology
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / immunology
  • Tomography, X-Ray Computed
  • Triazoles / therapeutic use
  • Vincristine / therapeutic use

Substances

  • Antifungal Agents
  • Antineoplastic Agents, Phytogenic
  • Triazoles
  • Vincristine
  • posaconazole